INCY
★★★★☆ BuymistralIncyte Corporation
Healthcare · sector percentile 100
세션 움직임
$128.12
거래량 0.55× 평균
90/100 quant · tgt $127.13
RS60 +32.7% vs SPY · ADV$ 190.8M
세션 2026-08-26 · 스냅샷 — 실시간 호가 아님
직전 스캔 대비
2026-08-25 → 2026-08-26
참고용이며 매수/매도 신호가 아닙니다. 스캔 이력과 캐시된 뉴스·공시로 구성됩니다.
스냅샷 시세
세션 2026-08-26 · 스캔 2026-08-26 · 푸시 08-26 18:57 ET · 애프터아워 (오래됨)
시세 상세 보기시세 상세 숨기기
- 종가/스캔가
- $129.72
- 전일 종가
- $129.72
- 푸시 최신가
- $128.12 (오래됨) · 08-26 18:57 ET · 애프터아워
- 세션 시가
- $129.18
- 직전 세션 범위
- $127.77 – $129.53
- 52주 범위
- $81.09 – $132.60
- 세션 거래량
- 800,046
- 평균 거래량 (20일)
- 1,447,047
- 시가총액
- $26.29B
- PER (TTM)
- 16.52
- Forward PER
- 14.51
- 배당 수익률
- 0.00%
- 1년 목표가 추정
- $127.13
- 다음 실적
- 2026-10-27
Snapshot quote — last daily session bars and scan fundamentals. Not live bid/ask or intraday quotes. 프리/애프터 시세는 유동성이 얇아 정규장과 다를 수 있습니다.
$1,000.00 넣었다면 지금
1년 전
$1,510.14
+51%
5년 전
$1,692.92
+69%
Price path only from cached daily closes (adjusted when available). Not dividends cash, fees, or advice.
시장 브리핑
선별된 요약입니다 — 매매 신호가 아닙니다. 헤드라인·링크는 제공된 그대로 표시됩니다.
- Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.
Benzinga · 2026-08-21
- Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Benzinga · 2026-08-21
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.
SeekingAlpha · 2026-08-20
Price Chart
Daily prices from cache
Loading price history…
AI Analysis
- Bull Thesis — Incyte's 92.61 quant score reflects strong revenue/EPS growth (37.7% YoY), 20.3% FCF margin, and 30.7% ROE, underpinned by JAK inhibitor pipeline momentum and expanding oncology portfolio.
- Risks — Form 4 insider selling cluster (2 trades in 14 days) and -15 disclosure score signal potential overhang despite strong fundamentals.
- Target Upside — Mean target of $127.13 implies 2.1% downside vs. $129.72 price, but pipeline catalysts (e.g., ruxolitinib, pemigatinib) could drive upside beyond consensus.
Score History
22 days of scans. Daily batch adds the next weekday automatically while the API is running.
- DatePriceChgScoreRating
- 2026-08-26$129.72+$1.7489.6Buy
- 2026-08-25$127.98+$0.1789.6Buy
- 2026-08-24$127.81+$0.5989.6Buy
- 2026-08-21$127.22−$1.2589.6Buy
- 2026-08-20$128.47+$5.0089.6Buy
- 2026-08-19$123.47−$0.0390.1Strong Buy
- 2026-08-18$123.50+$3.3490.1Strong Buy
- 2026-08-17$120.16−$0.3691.0Strong Buy
- 2026-08-14$120.52+$0.4090.9Strong Buy
- 2026-08-13$120.12−$0.9591.0Strong Buy
- 2026-08-12$121.07−$0.4890.7Strong Buy
- 2026-08-11$121.55+$0.9990.5Strong Buy
- 2026-08-10$120.56$0.0090.8Strong Buy
- 2026-08-09$120.56$0.0093.8Strong Buy
- 2026-08-08$120.56+$2.1893.8Strong Buy
- 2026-08-07$118.38−$1.4290.9Strong Buy
- 2026-08-06$119.80−$0.8091.0Strong Buy
- 2026-08-05$120.60+$2.1790.8Strong Buy
- 2026-08-03$118.43−$1.0990.9Strong Buy
- 2026-08-01$119.52−$0.1390.6Strong Buy
- 2026-07-31$119.65−$3.3490.5Strong Buy
- 2026-07-30$122.99—89.6Buy
Quant Breakdown
Short volume (FINRA)
Off-exchange short sale volume ratio vs recent sessions — not a squeeze forecast.
- Short / total
- 70.7%
- vs 20d (z)
- 0.90
- Short vol
- 194,699
- Status
- ok
Squeeze pressure score
full29/100
- Short leg
- 26
- Call leg
- 41
- Activity
- 0.0
- Call vol share
- 41.9%
- PCR (vol)
- 1.38
- Call OI share
- 48.2%
- ATM IV
- 41.6%
FINRA off-exchange short volume (TRF/ADF consolidated). Not short interest as % of float. Squeeze pressure score (0–100) — free composite of off-exchange short volume and (when available) call-side options activity. Not a probability that a squeeze will occur.
공시 점수 (Disclosure)
캐시된 SEC 공시 기반 News / Insider / Earnings 규칙 다리 — 참고용이며, beat/miss나 매수 신호가 아닙니다.
공시 점수
-15
- News
- 0
- Insider
- -15
- Earnings
- 0
아래 신호는 캐시된 공시의 규칙 히트입니다 — Risk / Constructive / Attention. Attention은 상승 신호가 아닙니다. 링크된 칩은 SEC 원문으로 이동합니다.
Risk (−)
Disclosure event score — rule-based view of recent SEC filings and earnings calendar. Not a prediction that price will move, and not earnings beat/miss.
실적 서프라이즈 (퀀트 맥락)
최근 퀀트 스캔에 캐시된 Yahoo/공개 펀더멘털 수치입니다 — 공시 이벤트 점수에 합산되지 않으며 매수 신호가 아닙니다. 최신 발표보다 늦을 수 있습니다.
최근 보고 서프라이즈 +0.4%
Filings & events
Recent SEC disclosures and earnings dates — context only, not a trade signal.
- Next earnings
- 2026-10-27yahoo_calendar
- Last earnings
- —
- SEC ↗42026-08-20
FORM 4
- SEC ↗42026-08-14
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-07
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗42026-08-04
FORM 4
- SEC ↗10-Q2026-07-28
10-Q
- SEC ↗8-K2026-07-28
8-K
- SEC ↗42026-07-27
FORM 4
- SEC ↗42026-07-27
FORM 4
SEC filings as reported; earnings dates may come from Yahoo calendar. Context only — not investment advice and not a prediction that price will move on a filing or event.